Latest News for TLPPF
Telix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets. TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622 million. Lead asset TLX591-Tx advances in phase 3 for mCRPC, while TLX250-Tx targets ccRCC in both monotherapy and combination trials.
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
Telix Pharmaceuticals Limited (NASDAQ: TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue.
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for TLPPF.
Senate Trading
No Senate trades found for TLPPF.
U.S. House Trading
No House trades found for TLPPF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.